Eduardo Richardet

机构：Instituto Oncológico de Córdoba

发表论文 100 篇 · 总被引 6714 次 · h-index 18

代表论文

• The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021 · npj Breast Cancer · 被引 282)
• First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update (2021 · ESMO Open · 被引 192)
• First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations (2022 · Journal of Thoracic Oncology · 被引 102)
• Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial (2024 · European Journal of Cancer · 被引 83)
• Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial (2024 · Journal for ImmunoTherapy of Cancer · 被引 63)
• Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA (2025 · ESMO Open · 被引 32)